PRESS RELEASE | SCIENTIFIC SESSIONS 2026 EMBARGOED UNTIL MONDAY, NOVEMBER 2, 2026 • 4:00 A.M. CENTRAL TIME Research spans coronary plaque, Agatston-2.0, cardiac chambers, lung cancer and chest X-ray AI; visit Booth 641 throughout the Chicago exhibits. Chicago, Illinois — November 2, 2026 — HeartLung Corporation (HeartLung.AI) will present eight accepted scientific abstracts at the American Heart Association (AHA) Scientific Sessions 2026, taking place November 6–9 at McCor
Company-record scientific program shows how AI can uncover coronary, chamber, valvular, plaque and lung cancer risk insights from routine CT. MUNICH, Germany, September 1, 2026- HeartLung.AI today announced the successful completion of a company-record scientific program at ESC Congress 2026 in Munich, where its investigators and academic collaborators presented 10 studies advancing artificial intelligence for cardiovascular prevention, coronary calcium assessment, cardiac ch
20-year MESA analysis finds CT-derived muscle quality predicts COPD more strongly than emphysema-like lung measures. HOUSTON, Texas - August 7, 2026 - HeartLung.AI today announced that the Radiological Society of North America (RSNA) has featured a major research publication demonstrating the potential of artificial intelligence-derived myosteatosis measurements from coronary artery calcium (CAC) CT scans to predict future chronic obstructive pulmonary disease (COPD). The ded
Complementary MESA analyses validate AI-derived cardiac chamber volumetry from non-gated, non-contrast CT for opportunistic heart failure and atrial fibrillation risk assessment HOUSTON - July 16, 2026 - HeartLung.AI announced the acceptance of two complementary studies in the American Journal of Preventive Cardiology demonstrating that artificial intelligence can extract clinically meaningful cardiac chamber measurements from routine non-gated, non-contrast chest CT and asse